Answers are grounded in this paper and cite their sources.
Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant orphan disease, leading to malformations of blood vessels. Regarding the pandemic, both, the course of COVID-19 infection and the response to the vaccination and its pos- sible side effects, such as increased bleeding episodes, are still poorly investigated. Methodology: Retrospective single-center cohort study at the Department of Otolaryngology / Head & neck Surgery (University Hospital of Zurich, Switzerland) between February 14th and March 21th 2022. Among the 32 eligible adult patients with HHT, we collected patient- and disease-specific characteristics. The course of a COVID-19 infection including severity of the disease and symptoms were noted. We assessed changes in the Hereditary Hemorrhagic Telangiectasia Epistaxis Severity Score (HHT-ESS) before and after vaccination. Results: Out of the 32 patients, 5 patients suffered a COVID-19 infection, thereby mainly experiencing loss of taste and smell and cough. No significant change of the HHT-ESS before and after vaccination was observed. The median HHT-ESS before and after the vaccination was 4.06. Conclusions: There was no significant change in bleeding severity (HHT-ESS) before and after COVID-19 vaccination. Based on these findings, the vaccination for HHT patients does not seem to worsen the further course of the disease. The overall symptoms, risks and complications after Sars-CoV-2 vaccination and infection seem to be comparable to the general population.
No takes yet. Share an insight, caveat, or question.
Gantert et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: